Table 3.
Selected prior studies of articulating spacers
| Study | Year | Spacer type | Number of knees | Mean followup (months) | Reinfection/persistent infection rate (%) | Average flexion (°) |
|---|---|---|---|---|---|---|
| Hofmann et al. [16] | 1995 | AOC | 26 | 30 | 0 | 106 |
| Emerson et al. [10] | 2002 | AOC | 22 | 44 | 9 | 108 |
| Hofmann et al. [15] | 2005 | AOC | 50* | 74 | 12 | 104 |
| Cuckler [8] | 2005 | AOC | 44 | 64 | 2.3 | |
| Pietsch et al. [26] | 2006 | AOC | 33 | 28 | 9 | NA |
| Jämsen et al. [20] | 2006 | AOC | 24 | 25 | 9 | 104 |
| Huang et al. [17] | 2006 | AOC | 21 | 52 | 4.7 | 97.6 |
| Fehring et al. [11] | 2000 | Custom-molded cement spacer | 15 | 24 | 6.6 | NA |
| Durbhakula et al. [9] | 2004 | SMC | 24 | 33 | 8.3 | 104 |
| Pitto et al. [27] | 2005 | Preformed cement spacer | 21 | 24 | 0 | 94 |
| Jämsen et al. [20] | 2006 | SMC | 10 | 48 | 20 | 92 |
| Freeman et al. [12] | 2007 | SMC | 48 | 62 | 5.3 | NA |
* This study includes the 26 knees from the authors’ prior study [16]; AOC = autoclaved original component; NFC = new femoral component; SMC = silicon mold component; NA = not available.